PDCD1 and neoplasm: Monoclonal antibodies that block immune checkpoint proteins, as anti- programmed cell death-1 (PD-1) and PD-Ligand-1 (PD-L1), thus enhancing the anti-tumor immune response, have demonstrated remarkable efficacy against multiple cancers, including melanoma [111].